Musical chairs as AstraZeneca hires Roche Pharma COO Soriot as new CEO
This article was originally published in Scrip
AstraZeneca has appointed Roche Pharma Chief Operating Office Pascal Soriot as the company's Chief Executive Officer. He will take on his new responsibilities and join the AstraZeneca PLC board as an Executive Director on 1 October 2012. Until then, Simon Lowth will remain as AstraZeneca's Interim Chief Executive Officer after which he will resume his responsibilities as Chief Financial Officer and AstraZeneca board member.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.